Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-689 DDI with CYP3A Modulators and Rabeprazole
NCT05602597Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amdizatinib in lymphoma (4 arms), sponsored by HUTCHMED. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Time t, Area Under the Concentration-Time Curve From Time Zero to Infinity and 1 more. Started Jun 2022; status: completed.
02
Drugs
amdizatinib
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05602597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602597.